INTRODUCCIÓN: REVISIÓN CRITICA DEL PROBLEMA

REFERENCIAS BIBLIOGRÁFICAS
217. Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, Selvin E. The
association of hemoglobin a1c with incident heart failure among people without diabetes:
the atherosclerosis risk in communities study. Diabetes. 2010 Aug;59(8):2020-6.
218. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC,
Holman RR. Association of glycaemia with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ.
2000 Aug 12;321(7258):405-12.
219. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from posthoc analyses of the CIBIS
II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart
Fail. 2001 Aug;3(4):469-79.
220. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH,
Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces
dose-related improvements in left ventricular function and survival in subjects with chronic
heart failure. MOCHA Investigators. Circulation. 1996 Dec 1;94(11):2807-16.
221. Kamalesh M, Nair G. Disproportionate increase in prevalence of diabetes among patients
with congestive heart failure due to systolic dysfunction. Int J Cardiol. 2005 Mar
10;99(1):125-7.
222. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes:
prevalence, incidence, and risk factors. Diabetes Care. 2001 Sep;24(9):1614-9.
223. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular
disease: the Framingham study. Diabetes Care. 1979 Mar-Apr;2(2):120-6.
224. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, Grobbee DE. The
prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J.
2001 Aug;22(15):1318-27.
225. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum
H, McMurray JJ. Diabetes, left ventricular systolic dysfunction, and chronic heart failure.
Eur Heart J. 2008 May;29(10):1224-40.
226. Kamalesh M. Diabetes and prognosis: are systolic and diastolic heart failure different? Heart.
2009 Mar;95(3):178-9.
227. Smit AJ, Lutgers HL. The clinical relevance of advanced glycation endproducts (AGE) and
recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem.
2004 Oct;11(20):2767-84.
228. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M,
Przysiecki C, Shaw A,. Survey of the distribution of a newly characterized receptor for
advanced glycation end products in tissues. Am J Pathol. 1993 Dec;143(6):1699-712.
229. Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellularmatrix gene
expression. Nephrol Dial Transplant. 1996;11 Suppl 5:62-5.
230. Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M,
Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H.. Advanced
glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J
Mol Cell Cardiol. 2002 Oct;34(10):1425-31..
231. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial
compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation.
1996 May 15;93(10):1905-12.
232. Schäfer S, Huber J, Wihler C, Rütten H, Busch AE, Linz W.. Impaired left ventricular
relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-
(carboxymethyl) lysine. Eur J Heart Fail. 2006 Jan;8(1):2-6.
233. Berg TJ, Snorgaard O, Faber J, Torjesen PA, Hildebrandt P, Mehlsen J, Hanssen KF. Serum
levels of advanced glycation end products are associated with left ventricular diastolic
function in patients with type 1 diabetes. Diabetes Care. 1999 Jul;22(7):1186-90.
237